Join the #IceBucketChallengeSupport an ALS EventEvents CalendarHealthcare ProvidersClinical TrialsHelp End ALSALS and Youth

Bernice Ramsay Innovation Grants

2014 Discovery Grant 

The discovery grant program has been established to encourage new basic research focused on identifying causes of or treatments for ALS. The goal of this program is develop novel methodology directly applicable to ALS, or to attract investigators from related fields who bring new expertise to ALS research. The spirit is of “high risk/potentially high impact”.

Up to four grants will be awarded in 2014 ($50,000-$100,000 per one year grant).
Application deadline: August 1, 2014.

Downloads:

Discovery Grant Terms of Reference

Application Face Page (word)

Application Face Page (pdf)

ALS Canada would like to congratulate the recipients of the 2013 Bernice Ramsay Discovery Grants.

 Richard Robitaille, PhD: Université de Montréal
 (co-applicant: Danielle Arbour, PhD)

 "Restoring in vivo glial functions at the neuromuscular junction in ALS: A  global approach"

 

 

 

 Neil Cashman, MD, FRCP(C), CAHS: University of British Columbia
 (co-applicants: Judith ‘Max’ Silverman, PhD and Leslie Grad, PhD)

 “Mechanisms of extracellular transmission and propagation of misfolded SOD1:  implications for ALS pathobiology”

 

 

 

2013 Bernice Ramsay Discovery Grant Terms of Reference

Previous recipients include:

Avi Chakrabartty, PhD: University of Toronto
(co-applicant: Christine Vande Velde, PhD)

Regulation of the proteomic and transcriptomic composition of stress granules by TDP-43

Neil Cashman, MD, FRCP(C), CAHS: University of British Columbia
Propagated protein misfolding of SOD1 in ALS

Dr. Martin Duennwald, PhD: Western University
(co-applicants: Kathryn Volkening, PhD and Michael J. Strong, MD, FRCP(C), FAAN, FCAHS)

RGNEF mediates aberrant RNA metabolism in ALS

Dr. François Gros-Louis, PhD: Laval University
(co-applicants: Nicolas Dupré, MD, MSc and François Berthod, PhD)
Diagnostic test for ALS – reconstructed skin studies, based on biopsies ($50,000)

Blair Leavitt, MD, PhD: University of British Columbia
(co-applicant: Kevin Park, PhD)
Pathological characterization of G93A mouse model of ALS following ASO-mediated MyoD knockdown

Sanjay Kalra, MD, FRCPC and Herbert Yang, PhD: University of Alberta  (2011)
Characterization of cerebral degeneration in ALS using MRI-based texture analysis

Edor Kabashi, PhD and Pierre Drapeau, PhD: University of Montreal (2011)
Characterization of C9ORF72 intronic expansions and genetic interaction with TDP-43

Heather Durham, PhD: McGill University (2010)
 The role of PRMT1-mediated methylation in a model of fALS caused by mutations in TLS/FUS (http://hmg.oxfordjournals.org/content/21/1/136.long)

Douglas P. Munoz, PhD: Queen’s University (2010)
Using eye movements and functional brain imaging to investigate cognitive deficits in ALS

Janice Robertson, PhD: University of Toronto (2010)
Per 28: a biomarker for ALS

Victor Rafuse, PhD: Dalhousie University (2009)
Induced pluripotent stem (iPS) cell-derived motor neurons: a model system for studying/treating sporadic ALS

Lorne Zinman, MD and Yana Yunusova, PhD: University of Toronto (2009)
Neural mechanisms of cognitive and bulbar motor decline in ALS

Avijit Chakrabartty, PhD: University of Toronto (2008)
Composition of ALS pathological inclusion bodies using a novel proteomics technique

Alex Parker, PhD: University of Montreal (2008)
Investigating the physiological consequences of TDP-43 mutations in a simple model system (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0031321)
 

2014 Clinical Research Fellowship (competition now open!)

The Bernice Ramsay Clinical Research Fellowship supports specialized training in clinical care and research skills related to amyotrophic lateral sclerosis (ALS).

Up to $200,000 will be awarded in this cycle ($100,000 per year over two years).

ALS Canada is proud to congratulate Dr. Amanda Fiander as the recipient of the 2014 Bernice Ramsay Clinical Research Fellowship. Dr. Fiander will train with Dr. Sameer Chhibber and Dr. Lawrence Korngut at the University of Calgary with a research component centred on a Phase II clinical trial of a novel therapeutic compound for the treatment of ALS (A Phase II Randomized Placebo Controlled Trial testing Withania somnifera in Volunteers with Amyotrophic Lateral Sclerosis (ALS).

Previous recipients include:

Amer Ghavanini, MD, PhD: London Health Sciences Centre (2011)
A new method of estimation of the number of motor units for clinical research in Amyotrophic lateral sclerosis (ALS)

Vincenzo Santo Basile, MD: Sunnybrook Health Sciences (2009)
Electromyography (EMG) and the diagnosis of ALS, multiple drug trials and the development of a molecular genetics program

2008 Betty Norman Clinical Fellowship in ALS Research

Kerri Schellenberg, MD, FRCPC; University of Alberta

Breaking bad news in amyotrophic lateral sclerosis: the need for medical education

For more information contact:
David Taylor, PhD
Director of Research
ALS Canada
3000 Steeles Avenue East, Suite 200
Markham, Ontario L3R 4T9
Toll Free: 1-800-267-4257 | ext. 202 | dt@als.ca